The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent

医学 经皮冠状动脉介入治疗 传统PCI 支架 临床终点 心肌梗塞 内科学 靶病变 心脏病学 药物洗脱支架 急性冠脉综合征 外科 随机对照试验
作者
Matteo Nardin,Carlo Andrea Pivato,Davide Cao,Samantha Sartori,Zhongjie Zhang,Birgit Vogel,Johny Nicolas,Mauro Chiarito,Hanbo Qiu,Jaya Chandrasekhar,Alessandro Spirito,Alexandre Abizaid,Evald Høj Christiansen,Antonio Colombo,Robbert J. de Winter,Michael Haude,Lars Jakobsen,Lisette Okkels Jensen,Mitchell W. Krucoff,Ulf Landmesser,Shigeru Saïto,Harry Suryapranata,Giuseppe De Luca,George Dangas,Roxana Mehran
出处
期刊:International Journal of Cardiology [Elsevier BV]
卷期号:370: 149-155 被引量:3
标识
DOI:10.1016/j.ijcard.2022.10.133
摘要

COMBO (OrbusNeich Medical, Hong Kong) is a dual-therapy coronary stent featuring sirolimus as antiproliferative drug and an anti-CD34+ antibody coating to attract endothelial progenitor cells favoring rapid stent re-endothelization. The Mega COMBO collaboration aimed to evaluate the performance of the COMBO stent in a large contemporary cohort of patients undergoing percutaneous coronary intervention (PCI).Patient-level data of subjects undergoing PCI with the COMBO stent from the REMEDEE-Trial, REMEDEE-OCT, HARMONEE, REDUCE, SORT OUT X, REMEDEE-Registry and MASCOT studies were pooled together. The primary endpoint was 1-year target lesion failure (TLF), a composite of cardiovascular death, target vessel myocardial infarction (TV-MI) or clinically driven target lesion revascularization (CD-TLR). Secondary outcomes were the individual components of the primary endpoint and stent thrombosis (ST). Endpoints were evaluated against performance goals based on the EAPCI (the European Association of Percutaneous Coronary Intervention) recommendations for new drug-eluting stents.A total of 6753 patients (mean age 63.7 ± 11.4 years, 23% women) were included. At 1-year follow-up, TLF occurred in 303 (4.6%) patients. The rates of cardiovascular death, TV-MI, and CD-TLR were 1.3%, 1.8%, and 2.5%, respectively. The rate of definite/probable ST was 0.73%, early ST (<1 month) was 0.48%, while late ST (1-12 months) was 0.26%. The performance goals were met for all of the evaluated endpoints.This large patient-level pooled analysis provides a comprehensive outline of the performance of the dual-therapy COMBO stent. The low rates of primary and secondary endpoints suggest that this stent technology may be a good alternative to other contemporary drug eluting coronary stent platforms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
qq完成签到,获得积分10
2秒前
王二哈完成签到,获得积分10
3秒前
行者无疆发布了新的文献求助10
4秒前
令散内方完成签到,获得积分10
4秒前
外向的雁玉完成签到,获得积分10
4秒前
慧灰huihui发布了新的文献求助10
5秒前
Ava应助Desire采纳,获得10
6秒前
量子星尘发布了新的文献求助10
9秒前
风信子完成签到,获得积分10
9秒前
小熊完成签到 ,获得积分10
11秒前
15秒前
shu完成签到,获得积分10
15秒前
15秒前
勤奋的毛豆完成签到,获得积分10
18秒前
行者无疆完成签到,获得积分10
18秒前
19秒前
Jackylee完成签到,获得积分10
19秒前
careyzhou发布了新的文献求助10
20秒前
舒心之云完成签到,获得积分10
22秒前
Desire发布了新的文献求助10
22秒前
独自受罪完成签到 ,获得积分10
23秒前
甘蓝型油菜完成签到,获得积分10
24秒前
Distance发布了新的文献求助10
25秒前
大橙子发布了新的文献求助10
26秒前
毛哥看文献完成签到 ,获得积分10
26秒前
Desire完成签到,获得积分10
28秒前
AiQi完成签到 ,获得积分10
29秒前
月月鸟完成签到 ,获得积分10
30秒前
陈永伟完成签到,获得积分10
32秒前
传奇3应助qq采纳,获得10
32秒前
feihua1完成签到 ,获得积分10
33秒前
大轩完成签到 ,获得积分10
34秒前
miemie66完成签到,获得积分10
35秒前
36秒前
Sun1c7完成签到,获得积分10
36秒前
大仁哥完成签到,获得积分10
36秒前
qqy完成签到,获得积分10
37秒前
失眠的香菇完成签到 ,获得积分10
39秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022